Chronic leukemia

536,781views

Chronic leukemia

Watch later

Watch later

Nernst equation
Cytoskeleton and intracellular motility
Cell signaling pathways
Resting membrane potential
Gene regulation
Epigenetics
Nuclear structure
DNA structure
Transcription of DNA
Amino acids and protein folding
Necrosis and apoptosis
Endometrial hyperplasia and cancer: Clinical
Lung cancer and mesothelioma: Pathology review
Metaplasia and dysplasia
Oral cancer
Testicular cancer
Lung cancer
Asthma
Atrial septal defect
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Acute respiratory distress syndrome
Angina pectoris
Aortic valve disease
Bronchiectasis
Chronic bronchitis
Chronic venous insufficiency
Coarctation of the aorta
Deep vein thrombosis
Emphysema
Endocarditis
Gas exchange in the lungs, blood and tissues
Heart failure
Mitral valve disease
Cor pulmonale
Heart failure: Pathology review
Myocarditis
Diabetes mellitus: Pathology review
Adrenocorticotropic hormone
Chlamydia trachomatis
Cortisol
Abnormal uterine bleeding: Clinical
Cushing syndrome
Endometriosis
Glucagon
Glucocorticoids
Herpes simplex virus
HIV (AIDS)
Hypothyroidism: Pathology review
Hypothyroidism
Insulin
Neisseria gonorrhoeae
Pelvic inflammatory disease
Polycystic ovary syndrome
Benign prostatic hyperplasia
Thyroid hormones
Testosterone
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Primary adrenal insufficiency
Hyperthyroidism: Pathology review
Chronic leukemia
Anemia of chronic disease
Hemophilia
Heparin-induced thrombocytopenia
Hypocalcemia
Hypermagnesemia
Hypokalemia
Hypomagnesemia
Inflammation
Innate immune system
Complement system
Iron deficiency anemia
Leukemias: Pathology review
Platelet disorders: Pathology review
Sickle cell disease (NORD)
Type IV hypersensitivity
Vaccinations
Acute pyelonephritis
Celiac disease
Cirrhosis
Congenital disorders: Clinical
Appendicitis
Autoimmune hepatitis
Bowel obstruction
Chronic cholecystitis
Chronic pyelonephritis
Crohn disease
Gastroesophageal reflux disease (GERD)
Nephrotic syndromes: Pathology review
Irritable bowel syndrome
Lower urinary tract infection
Biliary colic
Peptic ulcer
Renal failure: Pathology review
Urinary tract infections: Pathology review
Viral hepatitis
Pancreatitis: Pathology review
Alcohol-associated liver disease
Ulcerative colitis
Medullary cystic kidney disease
Small bowel ischemia and infarction
Chronic kidney disease
Acute cholecystitis
Skin cancer
Autosomal trisomies: Pathology review
Selective permeability of the cell membrane
Free radicals and cellular injury
Pericarditis and pericardial effusion
Peripheral artery disease
Cauda equina syndrome
Cranial nerves
Dementia: Pathology review
Arteriovenous malformation
Bipolar and related disorders
Seizures and epilepsy
Generalized anxiety disorder
Headaches: Pathology review
Huntington disease
Ischemic stroke
Major depressive disorder
Meningitis
Migraine
Multiple sclerosis
Myasthenia gravis
Panic disorder
Parkinson disease
Alzheimer disease
Approach to abnormal uterine bleeding in reproductive-aged patients: Clinical sciences
Coagulation disorders: Pathology review
Factor V Leiden
Hodgkin lymphoma
Disseminated intravascular coagulation
Non-Hodgkin lymphoma
Introduction to the immune system
Acute pancreatitis
Approach to congenital heart diseases (acyanotic): Clinical sciences
Acne vulgaris
Atopic dermatitis
Back pain: Pathology review
Bone disorders: Pathology review
Burns
Osteoarthritis
Osteoporosis
Paget disease of bone
Psoriasis
Rheumatoid arthritis
Varicella zoster virus
Introduction to pharmacology
Drug administration and dosing regimens
Enzyme function
Pharmacokinetics: Drug metabolism
Pharmacokinetics: Drug elimination and clearance
Pharmacokinetics: Drug absorption and distribution
Pharmacodynamics: Drug-receptor interactions
Pharmacodynamics: Desensitization and tolerance
Pharmacodynamics: Agonist, partial agonist and antagonist
Opioid agonists, mixed agonist-antagonists and partial agonists
Opioid use disorder
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Opioid antagonists
Anticoagulants: Direct factor inhibitors
Anticoagulants: Heparin
Anticoagulants: Warfarin
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Role of Vitamin K in coagulation
Loop diuretics
Miscellaneous lipid-lowering medications
Potassium sparing diuretics
Adrenergic antagonists: Alpha blockers
Calcium channel blockers
Adrenergic antagonists: Beta blockers
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Class II antiarrhythmics: Beta blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Class I antiarrhythmics: Sodium channel blockers
Thiazide and thiazide-like diuretics
ACE inhibitors, ARBs and direct renin inhibitors
Positive inotropic medications
Anti-mite and louse medications
Antimalarials
Hepatitis medications
Anthelmintic medications
Integrase and entry inhibitors
Antimetabolites: Sulfonamides and trimethoprim
Azoles
Cell wall synthesis inhibitors: Cephalosporins
Cell wall synthesis inhibitors: Penicillins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Echinocandins
Herpesvirus medications
Mechanisms of antibiotic resistance
Miscellaneous cell wall synthesis inhibitors
Miscellaneous protein synthesis inhibitors
Neuraminidase inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Protein synthesis inhibitors: Aminoglycosides
Protein synthesis inhibitors: Tetracyclines
Antihistamines for allergies
Miscellaneous antifungal medications
Antituberculosis medications
Androgens and antiandrogens
Aromatase inhibitors
Estrogens and antiestrogens
PDE5 inhibitors
Progestins and antiprogestins
Uterine stimulants and relaxants
Acid reducing medications
Antidiarrheals
Laxatives and cathartics
Non-corticosteroid immunosuppressants and immunotherapies
Hyperthyroidism medications
Hypoglycemics: Insulin secretagogues
Hypothyroidism medications
Insulins
Miscellaneous hypoglycemics
Mineralocorticoids and mineralocorticoid antagonists
Sympatholytics: Alpha-2 agonists
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Atypical antipsychotics
Atypical antidepressants
Typical antipsychotics
Lithium
Monoamine oxidase inhibitors
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Anti-parkinson medications
Tricyclic antidepressants
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Migraine medications
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Antigout medications
Folate (Vitamin B9) deficiency
Vitamin D
Fat-soluble vitamin deficiency and toxicity: Pathology review
Approach to viral exanthems (pediatrics): Clinical sciences
Mumps virus
Measles virus
Rubella virus
Bordetella pertussis (Whooping cough)
Poliovirus

Transcript

Watch video only

With chronic leukemia, “leuk” refers to white blood cells, and “emia” refers to the blood; so in chronic leukemia there are lots of partially developed white blood cells in the blood over a long period of time.

These partially developed white blood cells interfere with the development and function of healthy white blood cells, platelets, and red blood cells.

Now, every blood cell starts its life in the bone marrow as a hematopoietic stem cell.

Hematopoietic stem cells are multipotent -- meaning that they can give rise to both myeloid or lymphoid blood cells.

If a hematopoietic stem cell develops into a myeloid cell, it’ll mature into an erythrocyte -- or a red blood cell, a thrombocyte -- or a platelet, or a leukocyte -- or a white blood cell, like a monocyte or granulocyte.

Granulocytes are cells with tiny granules inside of them -- they include neutrophils, basophils, and eosinophils.

If a hematopoietic stem cell develops into a lymphoid cell, on the other hand, it’ll mature into some other kind of leukocyte: a T cell, a B cell, or a natural killer cell, which are referred to as lymphocytes.

Once the various blood cells form, they leave the bone marrow, and travel around the blood, or settle down in tissues and organs like the lymph nodes and spleen.

Chromosomal abnormality in hematopoietic stem cells that are destined to become leukocytes is the most common cause of chronic leukemia.

Some examples of abnormalities include a chromosomal deletion, where part of a chromosome is missing, a trisomy, where there’s one extra chromosome, and a translocation, where two chromosomes break and swap parts with one another.

Now there are two types of chronic leukemia.

The first is chronic myeloid leukemia, CML, which is caused by a particular chromosomal translocation that affects granulocytes.

The second is chronic lymphocytic leukemia, CLL, which is caused by a variety of chromosomal mutations that affect lymphocytes, in particular B cells.

Both CML and CLL cause cells to mature only partially, and that’s a key distinction from acute leukemias where the cells don’t mature at all.

As a result, these abnormal, premature leukocytes don’t work effectively, which weakens the immune system.

In addition, the chromosomal changes alters the cell’s normal cell cycle.

As a result, in CML the cells start to divide way too quickly and in CLL the cell’s don’t die when they should -- and in both situations, we’re left with way too many of these premature cells.

So over time, premature leukocytes accumulate in the bone marrow, until eventually they spill out into the blood.

Now some of these guys settle down in organs and tissues across the body, but others keep circulating in the blood.

With a bunch of extra cells in the blood, all the healthy cells get “crowded out”, and it’s tough for them to survive with the extra competition for nutrients.

This causes cytopenias, or a reduction in the number of healthy blood cells, like anemia, which is a reduction of healthy red blood cells, thrombocytopenia, a reduction of healthy platelets, and leukopenia, or a reduction of healthy leukocytes.

In chronic myeloid leukemia, the most common cause is a chromosome translocation which results in a Philadelphia chromosome.

And that’s where a portion of chromosome 9’s long arm switches with a portion of chromosome 22’s long arm -- and we write that as t(9;22) -- t because it’s a translocation, and 9 and 22 because those are the chromosomes that switch genetic information.

This results in a modified chromosome 9 and modified chromosome 22, and it’s the chromosome 22 that’s called the Philadelphia chromosome.

So, in the Philadelphia chromosome, a chromosome 22 gene, which is the BCR gene, ends up sitting right next to a chromosome 9 gene, the ABL gene.

When they’re combined it forms a fusion gene called BCR ABL, which codes for a protein also called BCR ABL, which is a constitutively active tyrosine kinase, meaning that BCR ABL is like an “on/off” switch stuck in the “on” position.

Since BCR ABL helps control various cellular functions like cell division, having it always “on” forces myeloid cells to keep dividing quicker than they should, which causes a buildup of the premature leukocytes in the bone marrow, that eventually spill into the blood.

The premature leukocytes then move to the liver and spleen, causing swelling of those organs or “hepatosplenomegaly”.

And because these CML cells divide quicker than they should, there’s a high chance that further genetic mutations can happen!

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  5. "Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future" Cells (2021)
  6. "Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future" Cells (2021)
  7. "Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies" Journal of Clinical and Experimental Hematopathology (2020)
  8. "Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management" American Journal of Hematology (2019)